期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

帕金森病模型大鼠经药物治疗前后脑D_2受体与多巴胺含量的研究 被引量：2

Exploration of D_2 receptors and cotent of DA of striatum in hemi-parkinsonism model rats before and after Madopar treatment
下载PDF
导出
摘要 应用125I－IBZM大鼠脑D2受体放射自显影、高效液相－电化学检测器检测纹状体多巴胺（DA）及其代谢产物含量，对经美多巴治疗前后的帕金森病（PD）模型大鼠进行对照性研究。结果表明：经美多巴治疗后损毁侧纹状体／小脑125I－IBZM摄取比值为7．23±0．67，比健侧增高17．22±3．94％，但与治疗前组及治疗空白对照组比较。明显下降（P＜0．01）；美多巴治疗组损毁侧纹状体DA等含量较治疗前组及治疗空白对照组明显增高（P＜0．05）。说明美多巴治疗可以提高偏侧PD模型大鼠损毁侧纹状体DA的含量，并可以阻止并反转损毁侧纹状体D2受体的上调效应。 125I-IBZM autoradiographic analysis, HPLC-ECD were used to study therelationship between D2 receptors and the content of DA, HVA, DOPAC in striatumof hemi-parkinsonism model rats before and after Madopar treatment. After Madopartreatment, the striatum/cerebellum 125I-IBZM uptake ratio of lesioned side was 7.23±0.67, showed 17.22± 3.94% increasing as compared to the contralateral side, theincreasing were significantly declined compared with the pretreatment group andcontrol group (P<0.01). The DA, HVA, DOPAC levels in lesioned side striatum ofMadopar group were increased compared with the other two groups (P<0.05). All ofthe above verified that Madopar treatment can elevate DA levels of lesioned striatumin hemi-parkinsonism model rats, and thus prevent and reverse the up-regulation ofD2 receptors.
作者 林岩松 林祥通
机构地区 青岛医学院附属医院 上海医科大学附属华山医院
出处 《核技术》 CAS CSCD 北大核心 1998年第5期257-261,共5页 Nuclear Techniques
关键词 帕金森病 多巴胺 D2受体 IBZM 放射性标记 Parkinsonism, Dopamine D_2 receptor, IBZM, Dopamine
分类号 R817 [医药卫生—影像医学与核医学]
  • 相关文献

参考文献3

  • 1林岩松，核技术，1996年，19卷，641页
  • 2Kung M P，J Nucl Med，1991年，32卷，329页
  • 3冯林音，上海医科大学学报，1989年，9卷，84页

同被引文献19

  • 1Dresel SH, Kung MP, Huang XF, et al. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons. J Nucl Med,1999, 40: 660-666.
  • 2Kung HF, Guo YZ, Billings J, et al. Preparation and biodistribution of ^125IIBZM: a potential CNS D2 dopamine receptor imaging agent. Int J Rad Appl Instrum B, 1988, 15: 195-201.
  • 3Rinne UK, Laihinen A, Rinne JO, et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson' s disease. Mov Disord, 1990, 5: 55-59.
  • 4Rinno JO, Laihinen A, Ruottinen H, et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with ^11C-Raclopride. J Neurol Sci, 1995,132: 156-161.
  • 5Antonini A, Schwarz J, Oertel WH, et al. Long-term changes of striatal doapmine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and ^11C-Raclopride. Mov disord, 1997, 12:33-38.
  • 6Pirker W, Luger RM. Iodine-123-epidepride-SPECT: studies in Parkinson disease, multiple system atrophy and Huntington's disease[J].J Nucl Med,1997,38:1711-1717.
  • 7Verhoeff NPLG,Speelman JD,Kuiper MA,et al.Clinical significanoe of dopamine D2-receptors imaging with ^123 Ⅰ-iodobenzamide SPECT in patients with parkinsonism syndrome(A).In:de Deyn PP,Dierckx RA, Alavi A, (eds). A textbook of SPECT in neurology and psychiatry[ M]. London: Libbey, 1997.167-179.
  • 8Schwarz J,Tatsh K, Gagger T, et al.^123Ⅰ-IBZM binding compared with long-term clinical follow-up in patients with de novo patkinsonism[J]. Mov Disord, 1998,13:16-19.
  • 9Schwarz J,Tatsh K, Gasser T, et al. ^123Ⅰ-IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy[J]. Mov Disord, 1997,12 : 898-902.
  • 10Turjashi N, Lees A J, Brooks DJ. In vivo striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson' s disease patients with and without dyskinesias [J]. Neurology, 1997,49: 717-723.

引证文献2

二级引证文献21

核技术
1998年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部